SOMATOSTATIN ANALOGUE LANREOTIDE (IPSTYL)--TREATMENT OF ACROMEGALY
$40,417M01FY2000RRNIH
Massachusetts Institute Of Technology, Cambridge MA
Investigators
Linked publications & trials
Paper 20400410Paper 18657126Paper 18280316Paper 18278630Paper 18025896Paper 17636096Paper 16158084Paper 15883435Paper 15545977Paper 15531674Paper 15240605Paper 15138154Paper 15044663Paper 14647179Paper 14647177Paper 14634685Paper 14625206Paper 12936932Paper 12917718Paper 12730432Paper 12399276Paper 12045492Paper 11821342Paper 11600532Paper 11114177Paper 10974208
Abstract
To investigate the long-term safety and efficacy of Lanreotide in controlling acromegaly in terms of normalization of growth hormone (GH) and Insulin-like growth factor-I (IGF-I) levels, as well as monitoring for tumor response, and ability of drug to control/reduce symptoms associated with acromegaly.
View original record on NIH RePORTER →